DefiniGEN is a technology company.
DefiniGEN has raised $10.9M across 4 funding rounds.
DefiniGEN has raised $10.9M in total across 4 funding rounds.
DefiniGEN is a biotechnology company headquartered in Cambridge, UK, specializing in stem cell-derived human cell models for drug discovery, particularly revolutionizing liver models for efficacy and toxicology screening.[1][2][3] It builds scalable platforms like OptiDIFF to generate hepatocyte-like cells (HLCs) that mimic primary human cells, simulating liver disease pathophysiology and integrating CRISPR/Cas9 for rare disease modeling, serving pharmaceutical companies and researchers to minimize drug development risks, cut costs, and improve predictive testing.[1][3][5] With 11-50 employees and expansion into lung and pancreatic cells, DefiniGEN addresses key bottlenecks in toxicity testing where most drug candidates fail, providing consistent, functional cells for safer therapies.[3][4][5]
DefiniGEN was founded in April 2012 as a spin-out from the University of Cambridge's Anne McLaren Laboratory of Regenerative Medicine, industrializing the OptiDIFF stem cell production platform developed by Dr. Ludovic Vallier, Dr. Tamir Rashid, and Professor Roger Pedersen.[2][5] The idea emerged from expertise in induced pluripotent stem cells (iPSCs) and metabolic disease modeling, building on University IP and in-licensing Yamanaka iPSC technology from iPS Academia Japan.[2][5] Early traction came via Cambridge Enterprise Seed Funds, enabling rapid commercialization of HLCs for drug discovery and regenerative medicine, with pivotal moves like licensing lung stem cell tech from Cambridge to model diseases like cystic fibrosis.[4][5]
DefiniGEN rides the stem cell and organoid wave in biotech, addressing the 90%+ drug failure rate in clinical trials—especially liver toxicity—by providing human-relevant models over animal testing.[1][5] Timing aligns with surging iPSC adoption post-Yamanaka Nobel (2006) and CRISPR advancements, fueled by pharma's push for 3Rs (Replacement, Reduction, Refinement) in preclinical screening amid regulatory pressures.[4][5][6] Market forces like rising drug development costs ($2B+ per approval) and rare disease focus favor its scalable, disease-specific cells, influencing the ecosystem by accelerating lead optimization for metabolic disorders and enabling therapies inaccessible before.[2][5]
DefiniGEN is poised to expand beyond liver into lung and pancreas portfolios, leveraging new licenses for industrial-scale airway tissues and diabetes models to capture growing demand in personalized medicine.[4][5] Trends like AI-driven drug discovery and microphysiological systems (e.g., 3Rs Collaborative membership) will amplify its role, potentially through partnerships or acquisitions as pharma seeks predictive tools amid biotech funding rebounds.[6] Its influence may evolve from niche supplier to ecosystem leader in humanized assays, tying back to its core mission: slashing drug risks with game-changing cells that make development faster, safer, and more human-centric.[1][3]
DefiniGEN has raised $10.9M in total across 4 funding rounds.
DefiniGEN's investors include 24Haymarket, Business Growth Fund.
DefiniGEN has raised $10.9M across 4 funding rounds. Most recently, it raised $4.0M Venture Round in November 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2020 | $4.0M Venture Round | 24Haymarket, Business Growth Fund | |
| Oct 1, 2018 | $910K Venture Round | 24Haymarket | |
| May 1, 2016 | $2.0M Series B | 24Haymarket | |
| Jun 1, 2014 | $4.0M Series A | 24Haymarket |